10-Q: Cell MedX Corp. Reports Q1 2025 Results: Operating Expenses Rise Amidst Ongoing Financial Challenges

Cell MedX Corp.'s Q1 2025 report reveals increased operating expenses and a continued net loss, highlighting the company's ongoing financial challenges.

Summary

• Cell MedX Corp. reported its financial results for the first quarter of fiscal year 2025, ending August 31, 2024.
• The company experienced a net loss of $66,919, compared to a net loss of $76,953 in the same period last year.
• Operating expenses increased by 16.8% to $59,636, primarily due to new management fees and higher consulting costs.
• The company's cash balance decreased to $20,552 from $43,415 at the end of the previous quarter.
• Cell MedX has accumulated a deficit of $10,362,182 and faces substantial doubt about its ability to continue as a going concern.
• The company's working capital deficit increased to $908,730 from $826,455 at the end of the previous quarter.
• There were no revenue-generating activities during the quarter.
• The company funded operations with $75,000 from a private placement of common stock.

Sentiment

Score: 2

Explanation: The document paints a very negative picture of the company's financial health, with a going concern warning, significant losses, and a lack of revenue. The company's reliance on related party loans and private placements, along with the abandonment of R&D plans, further contribute to the low sentiment.

Positives

• The net loss decreased slightly compared to the same quarter last year, from $76,953 to $66,919.
• The company recorded a gain of $1,569 on forgiveness of debt due to balances exceeding the statute of limitations.
• The company received $75,000 from a private placement of common stock.

Negatives

• Operating expenses increased by 16.8% to $59,636, primarily due to new management fees and higher consulting costs.
• The company's cash balance decreased significantly to $20,552.
• The working capital deficit increased to $908,730.
• The company has accumulated a significant deficit of $10,362,182.
• There were no revenue-generating activities during the quarter.
• The company's research and development plans associated with the eBalance technology were abandoned due to financial difficulties.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to its accumulated deficit and lack of revenue.
• The company is dependent on additional financing from shareholders, debt, or equity to meet its obligations.
• The company faces intense competition from larger, well-established medical device and pharmaceutical companies.
• The company's products are subject to rigorous regulatory approvals, which can be costly and time-consuming.
• The company's intellectual property rights are crucial, and any infringement could adversely affect its financial results.
• The company's research and development efforts may not result in commercially successful products.
• The company may face safety concerns with its products, which could halt sales or reduce market acceptance.
• The company's stock is a penny stock, which limits shareholders' ability to sell their shares.
• The company has not paid and does not anticipate paying cash dividends on its common stock.

Future Outlook

The company's future is uncertain, with a dependence on additional financing and the attainment of profitable operations to continue as a going concern. Management is planning to mitigate the company's shortfall in funds through equity or debt financing.

Management Comments

• Management believes all adjustments necessary for a fair presentation of the results of operations and financial position have been included.
• Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.
• Management concluded that the disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information due to lack of segregation of duties.

Industry Context

The company operates in the highly competitive biotech industry, facing competition from established medical device and pharmaceutical companies. The market for diabetes and pain management is subject to rapid change and new product introductions, requiring Cell MedX to innovate and compete effectively.

Comparison to Industry Standards

• Cell MedX's lack of revenue and significant operating losses are not uncommon for early-stage biotech companies, but the magnitude of the accumulated deficit and the going concern warning are concerning.
• Compared to established medical device companies like Bayer Corp., Becton Dickinson Corp., and Johnson & Johnson, Cell MedX lacks the resources, market presence, and regulatory approvals.
• Many biotech companies in the early stages of development rely on venture capital and private funding, and Cell MedX's reliance on related party loans and private placements is a common but risky strategy.
• The company's abandonment of research and development plans due to financial difficulties is a significant setback compared to companies that are able to maintain their R&D efforts.

Corporate Governance

Related Party Transactions

• The company has significant transactions with related parties, including loans, advances, and management fees.
• Amounts due to related parties totaled $280,848 as of August 31, 2024.
• Notes and advances due to related parties totaled $332,407 as of August 31, 2024.
• Management fees incurred to the CEO and President were $22,500 for the three-month period ended August 31, 2024.
• Consulting fees incurred to the CFO were $7,500 for the three-month period ended August 31, 2024.
• Consulting fees incurred to an entity controlled by a director of the Company were $27,394 for the three-month period ended August 31, 2024.
• An entity controlled by a director and a significant shareholder, agreed to forgive a total of $3,165 the Company owed for royalties.

Stakeholder Impact

• Shareholders face a high risk of losing their investment due to the company's financial difficulties and going concern warning.
• Employees may face job insecurity due to the company's uncertain future.
• Creditors face a risk of not being repaid due to the company's lack of cash and significant debt.
• Customers and suppliers may be impacted by the company's potential inability to continue operations.

Next Steps

• The company needs to secure additional financing through debt or equity to continue operations.
• The company needs to address the lack of segregation of duties in its internal controls.
• The company needs to develop a plan to generate revenue and achieve profitability.

Key Dates

Keywords

Cell MedX, biotech, eBalance Technology, microcurrents, medical devices, financial results, net loss, operating expenses, working capital, going concern, related party transactions, debt financing, equity financing, regulatory approvals